Drug Trial Radar · NCT06663189
Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis)
Last checked: Nov 20, 2026Latest source record: Jan 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Jan 2025
Primary completion
Jan 2027
Study completion Jun 2029
Sponsor
- Lead sponsor
- University Hospital, Strasbourg, FranceAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Ministry of Health, France
- First posted
- Oct 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS) characterized by loss of motor and sensory function, that results from immune-mediated inflammation, demyelination and subsequent axonal damage. It is the most common cause of neurological disability in young adults, involving a long-term therapeutic follow-up. 85% of the patients are diagnosed with Relapsing-Remitting form of MS (RRMS). This form is characterized by clearly defined acute or subacute neurological symptoms (relapses) followed by periods of partial to complete recovery. Disease-modifying therapies (DMT) used to treat RRMS are immunomodulatory or suppressor molecules which have proven efficacy in limiting disease activity (decreasing relapse rate and delaying time to disease progression). However, the long-term safety of DMT is uncertain, as there is an increased risk of developing adverse events or infections (sometimes severe) such as observed in the last pandemic of COVID-19 (higher risk of infection), highlighting the need to reassess the benefit/risk ratio of maintaining immunomodulatory or suppressive therapy in the MS population. In elderly patients with comorbidity, this risk is further increased. To date, few studies on the discontinuation of treatment in elderly RRMS patients have been conducted. However, those available demonstrate that there was no difference in relapse rates between patients who continued or discontinued treatment. These results are consistent with immunosenescence studies in RRMS that suggested a negative correlation between relapse rate/inflammatory processes and age. On the contrary, there is evidence indicating a positive correlation between age and the number of infections. In addition, in the current context in France, it is important to take into account the medico-social cost associated with long-term treatments. In France, the average estimated annual cost per patient is 12,000€, more than half of which is attributed to medications.Furthermore, with age progression, an inversion of the benefit/cost assessment has been observed in treated patients. Considering these medical and medico-social factors, it is reasonable to question the value of continuing treatment in stable patients with RRMS over 55 years. This is a randomized, controlled, multicentric, open-label, parallel groups, 1:1 ratio non-inferiority clinical trial, comparing (1) a group that will stop treatment, to (2) a group that will continue treatment, over the course of 2 years, to determine the survival rate without MS activity defined clinically or by imaging. The patients in both arms will be followed over 2 years after randomization. 5 visits will be performed for all patients: inclusion/randomization visit (M0) and 4 follow-up visits every 6 months (M6, M12, M18, and M24). An additional phone call at M3 is planned.
Conditions
- Relapsing-remitting Multiple Sclerosis (RRMS)
Interventions
treatment withdrawalDrug
Patients will STOP their DMT
Usual DMT continuationDrug
Patients will continue their DMT during the trial as usual : Interferon-β (IFN-β), glatiramer acetate, dimethyl fumarate, teriflunomide or diroximel fumarate
MRIOther
Cerebral+spinal cord enhanced MRI (M0) Cerebral enhanced MRI (M6, Relapse early visit) Unenhanced cerebral MRI (M12, M18, M24, Relapse distant visit
Quality of Life questionnairesBehavioral
EQ-5D5L: EuroQol-5-Dimension 5 levels Burden of Treatment Questionnaire (BTQ self-administered questionnaires) Hospital Anxiety and Depression (HAD) questionnaire
Disability evaluation testsOther
EDSS: Expanded Disability Status Scale 25Foot/Walk 9-HPT:Nine Hole Peg Test
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to first clinical and/or radiological disease activity during a period of 2 years.Time frame: From enrollment to the end of study visit at 24 months
Locations
22 sites in 1 country. Site status is shown where the registry gives one.
CHU de Bordeaux-Hôpital Pellegrin
Bordeaux, France
CHU de Caen-Hôpital Côte de Nacre
Caen, France
CHU de Clermont-Ferrand-Hôpital Gabriel Montpied
Clermont-Ferrand, France
Assistance Publique des Hôpitaux de Paris (APHP)-Hôpital Henri Mondor
Créteil, France
CHU de Dijon-Hôpital du Bocage
Dijon, France
CH de Gonesse
Gonesse, France
CHU de Grenoble Alpes
La Tronche, France
Groupement des Hôpitaux de l'Institut Catholique de Lille Hôpital Saint Vincent de Paul
Lille, France
CHU de Lille-Hôpital Roger Salengro
Lille, France
CHU de Limoges-Hôpital Dupuytren
Limoges, France
Assistance Publique des Hôpitaux de Marseille (APHM)-Hôpital La Timone Adultes
Marseille, France
CHU de Montpellier-Hôpital G. De Chauliac
Montpellier, France
CHU de Nancy -Hôpital Central
Nancy, France
CHU de Nice-Hôpital Pasteur
Nice, France
CHU de Nîmes
Nîmes, France
Assistance Publique des Hôpitaux de Paris (APHP)-Hôpital Pitié-Salpêtrière
Paris, France
Fondation Ophtalmologique Rothschild
Paris, France
CHU de Rennes-C.H.R. Pontchaillou
Rennes, France
CHU de Rouen-Hôpital Charles Nicolle
Rouen, France
CHU Nantes -CIC de Neurologie
Saint-Herblain, France
Les Hôpitaux Universitaires de Strasbourg
Strasbourg, France
CHU de Tours
Tours, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.